Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Study shows CyberKnife system provides durable pain relief for trigeminal neuralgia patients

Accuray announced that data from a study of 138 patients with trigeminal neuralgia (TN) showed stereotactic radiosurgery (SRS) delivered with the CyberKnife system resulted in rapid and long-lasting pain relief, with minimal side effects.

The study, titled "Image-Guided Robotic Radiosurgery for Trigeminal Neuralgia," was published in the December 2017 issue of the peer-reviewed journal Neurosurgery and provides robust clinical data supporting the efficacy and safety of the system for TN patients.

 It is the largest single-center study of TN patients treated with the CyberKnife technology reported to date.

"This study is important because it reinforces that CyberKnife SRS provides unique benefits in the treatment of TN. Pain management goals were achieved and bothersome complications were rare even though a less invasive approach to delivering radiation was used," said Professor Pantaleo Romanelli, M.D., Centro Diagnostico Italiano, Milan, Italy.

"Importantly, we used a consistent treatment protocol for each patient that resulted in reproducible outcomes. This should provide confidence to other clinicians that they, too, can achieve similar clinical results."

TN is a disease often characterized by severe pain, with some patients describing it as the most atrocious pain human beings can suffer. Techniques like CyberKnife SRS may provide new hope for people living with this severe and challenging-to-treat medical condition.

Pain relief was achieved in 93.5 percent of patients after a median delay of three weeks after treatment

Stable pain control was maintained by 76 percent of patients three years after the first treatment. The remainder of the patients attained pain control after a second treatment

78.9 percent of patients were completely pain- and medication-free within six months after treatment

93.5 percent of patients were able to decrease the dose of medications intended to control pain throughout follow-up and finally cease pain medication

Overall, 18.1 percent of patients developed some sensory disturbance. Of these patients, 68 percent experienced the onset of complications after their second treatment; this is a typical side effect following re-irradiation

Accuray global medical and scientific affairs vice president Dr Fabienne Hirigoyenberry-Lanson said: "The frameless CyberKnife Robotic Radiosurgery System delivers radiation beams from multiple unique angles (non-isocentric approach) with sub-millimeter accuracy.”

Importantly, the CyberKnife® technology's unique image guidance and automatic beam correction capability enabled the precise dose targeting necessary to treat TN.

No head frame was required to obtain the pain control and side effect profile achieved with Gamma Knife, as reported in other studies.